• Arch Biopartners posted a net loss of CAD 521,009 for the quarter ended March 31, 2026, narrowing from CAD 551,581 a year earlier.
• Operating loss improved to CAD 511,659 from CAD 587,967 in the prior-year quarter, helped by no share-based compensation versus last year.
• Research expenses rose to CAD 118,210, while cash used in operating activities totaled CAD 108,120.
• Cash and cash equivalents climbed to CAD 436,765 from CAD 4,163 at the start of the quarter, supported by CAD 540,722 in financing cash inflows.
• Working capital deficit was CAD 3.64 million; the Phase II LSALT Peptide CS-AKI trial end date was pushed to March 2027 on slower Canadian approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arch Biopartners Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.